• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.亨廷顿病的遗传修饰物对运动和认知领域有不同的影响。
Am J Hum Genet. 2022 May 5;109(5):885-899. doi: 10.1016/j.ajhg.2022.03.004. Epub 2022 Mar 23.
2
Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington's disease knock-in mice is blocked by Mlh1 knock-out.范氏贫血蛋白 1(Fan1)缺失可促进亨廷顿病基因敲入小鼠中的体 CAG 重复扩展,而错配修复蛋白 1(Mlh1)缺失可阻断这一过程。
Hum Mol Genet. 2020 Nov 4;29(18):3044-3053. doi: 10.1093/hmg/ddaa196.
3
Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington disease.在亨廷顿病的体外人类模型中对 MMR 相关遗传修饰物的治疗验证。
Am J Hum Genet. 2024 Jun 6;111(6):1165-1183. doi: 10.1016/j.ajhg.2024.04.015. Epub 2024 May 14.
4
Genetic Modification of Huntington Disease Acts Early in the Prediagnosis Phase.亨廷顿病的基因修饰作用发生在疾病诊断前早期。
Am J Hum Genet. 2018 Sep 6;103(3):349-357. doi: 10.1016/j.ajhg.2018.07.017. Epub 2018 Aug 16.
5
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.谷氨酰胺编码 DNA 序列结构、体细胞 CAG 扩增和 DNA 修复基因突变的遗传关联研究,与亨廷顿病临床结局相关。
EBioMedicine. 2019 Oct;48:568-580. doi: 10.1016/j.ebiom.2019.09.020. Epub 2019 Oct 10.
6
FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.FAN1 通过稳定扩展的 HTT CAG 重复序列来修饰亨廷顿病的进展。
Hum Mol Genet. 2019 Feb 15;28(4):650-661. doi: 10.1093/hmg/ddy375.
7
Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease.基因表达谱补充了对亨廷顿病临床发病的基因组修饰物的分析。
Hum Mol Genet. 2020 Sep 29;29(16):2788-2802. doi: 10.1093/hmg/ddaa184.
8
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.CAG 重复序列而非多聚谷氨酰胺长度决定亨廷顿病发病时间。
Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036.
9
Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease.超越 CAG 重复:遗传学在亨廷顿病中的多方面作用。
Genes (Basel). 2024 Jun 19;15(6):807. doi: 10.3390/genes15060807.
10
A modifier of Huntington's disease onset at the MLH1 locus.MLH1基因座处亨廷顿病发病的一个修饰因子。
Hum Mol Genet. 2017 Oct 1;26(19):3859-3867. doi: 10.1093/hmg/ddx286.

引用本文的文献

1
Unstable FGF14 GAA repeat expansions in Indian ataxia patients: a broader phenotype and involvement of modifier loci?印度共济失调患者中不稳定的FGF14 GAA重复序列扩增:更广泛的表型及修饰基因座的参与?
J Hum Genet. 2025 Aug 20. doi: 10.1038/s10038-025-01390-6.
2
Huntington's disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion.亨廷顿舞蹈症连接酶1修饰变体可提高连接酶保真度并抑制体细胞中CAG重复序列的扩增。
bioRxiv. 2025 Jul 18:2025.07.15.664798. doi: 10.1101/2025.07.15.664798.
3
Double strand breaks drive toxicity in Huntington's disease mice with or without somatic expansion.双链断裂在有或没有体细胞扩增的亨廷顿舞蹈症小鼠中引发毒性。
bioRxiv. 2025 May 28:2025.05.27.654663. doi: 10.1101/2025.05.27.654663.
4
Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects.亨廷顿舞蹈病中体细胞扩增和临床表型的遗传修饰因子凸显了共同效应和组织特异性效应。
Nat Genet. 2025 Jun;57(6):1426-1436. doi: 10.1038/s41588-025-02191-5. Epub 2025 Jun 9.
5
is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.是X连锁肌张力障碍帕金森综合征中体细胞重复不稳定性的遗传修饰因子。
bioRxiv. 2025 May 16:2025.05.14.653432. doi: 10.1101/2025.05.14.653432.
6
Interventionally targeting somatic CAG expansions can be a rapid disease-modifying therapeutic avenue: Preclinical evidence.通过干预靶向体细胞CAG重复扩增可能是一条快速改善疾病的治疗途径:临床前证据。
bioRxiv. 2025 Apr 28:2025.04.25.650652. doi: 10.1101/2025.04.25.650652.
7
Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review.神经退行性疾病的分子机制与生物标志物:综述
Mol Biol Rep. 2025 Mar 26;52(1):337. doi: 10.1007/s11033-025-10463-w.
8
CAG Repeat Instability and Region-Specific Gene Expression Changes in the SCA12 Brain.SCA12 脑内的 CAG 重复序列不稳定性及区域特异性基因表达变化
Cerebellum. 2025 Mar 13;24(3):60. doi: 10.1007/s12311-025-01808-z.
9
Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases.基因组学和转录组学方法推动神经退行性疾病的诊断与预后研究。
Genes (Basel). 2025 Jan 24;16(2):135. doi: 10.3390/genes16020135.
10
Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.亨廷顿舞蹈症生物标志物的进展:十年文献计量分析与综合综述
Biology (Basel). 2025 Jan 26;14(2):129. doi: 10.3390/biology14020129.

本文引用的文献

1
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease.亨廷顿舞蹈症患者精神、认知及运动异常的发生时间与影响
Neurology. 2021 May 11;96(19):e2395-e2406. doi: 10.1212/WNL.0000000000011893. Epub 2021 Mar 25.
2
Huntington's Disease Pathogenesis: Two Sequential Components.亨廷顿病发病机制:两个连续的阶段。
J Huntingtons Dis. 2021;10(1):35-51. doi: 10.3233/JHD-200427.
3
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.美国国立卫生研究院生物医学高级研究与发展局(NHLBI)TOPMed 项目中对 53831 个不同基因组进行测序。
Nature. 2021 Feb;590(7845):290-299. doi: 10.1038/s41586-021-03205-y. Epub 2021 Feb 10.
4
Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease.基因表达谱补充了对亨廷顿病临床发病的基因组修饰物的分析。
Hum Mol Genet. 2020 Sep 29;29(16):2788-2802. doi: 10.1093/hmg/ddaa184.
5
Genetic and Functional Analyses Point to FAN1 as the Source of Multiple Huntington Disease Modifier Effects.遗传和功能分析表明 FAN1 是多种亨廷顿病修饰效应的来源。
Am J Hum Genet. 2020 Jul 2;107(1):96-110. doi: 10.1016/j.ajhg.2020.05.012. Epub 2020 Jun 25.
6
Huntingtin Lowering Strategies.亨廷顿蛋白降低策略。
Int J Mol Sci. 2020 Mar 20;21(6):2146. doi: 10.3390/ijms21062146.
7
Huntington's Disease Pathogenesis Is Modified In Vivo by Alfy/Wdfy3 and Selective Macroautophagy.亨廷顿病的发病机制可被 Alfy/Wdfy3 和选择性巨自噬在体内改变。
Neuron. 2020 Mar 4;105(5):813-821.e6. doi: 10.1016/j.neuron.2019.12.003. Epub 2019 Dec 30.
8
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.谷氨酰胺编码 DNA 序列结构、体细胞 CAG 扩增和 DNA 修复基因突变的遗传关联研究,与亨廷顿病临床结局相关。
EBioMedicine. 2019 Oct;48:568-580. doi: 10.1016/j.ebiom.2019.09.020. Epub 2019 Oct 10.
9
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.CAG 重复序列而非多聚谷氨酰胺长度决定亨廷顿病发病时间。
Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036.
10
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.MSH3改变亨廷顿舞蹈症和1型强直性肌营养不良症中的体细胞不稳定性和疾病严重程度。
Brain. 2019 Jun 19;142(7):1876-86. doi: 10.1093/brain/awz115.

亨廷顿病的遗传修饰物对运动和认知领域有不同的影响。

Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.

机构信息

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; Medical and Population Genetics Program, the Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Department of Biostatistics, School of Public Health, Yale University, New Haven, CT 06511, USA.

出版信息

Am J Hum Genet. 2022 May 5;109(5):885-899. doi: 10.1016/j.ajhg.2022.03.004. Epub 2022 Mar 23.

DOI:10.1016/j.ajhg.2022.03.004
PMID:35325614
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9118113/
Abstract

Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage. The largest studies have been limited to HD individuals with a rater-estimated age at motor onset. To capitalize on the wealth of phenotypic data in several large HD natural history studies, we have performed algorithmic prediction by using common motor and cognitive measures to predict age at other disease landmarks as additional phenotypes for GWASs. Combined with imputation with the Trans-Omics for Precision Medicine reference panel, predictions using integrated measures provided objective landmark phenotypes with greater power to detect most modifier loci. Importantly, substantial differences in the relative modifier signal across loci, highlighted by comparing common modifiers at MSH3 and FAN1, revealed that individual modifier effects can act preferentially in the motor or cognitive domains. Individual components of the DNA maintenance modifier mechanisms may therefore act differentially on the neuronal circuits underlying the corresponding clinical measures. In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7. These findings indicate that broadened discovery and characterization of HD genetic modifiers based on additional quantitative or qualitative phenotypes offers not only the promise of in-human validated therapeutic targets but also a route to dissecting the mechanisms and cell types involved in both the somatic instability and toxicity components of HD pathogenesis.

摘要

亨廷顿病 (HD) 的全基因组关联研究 (GWAS) 已经确定了六个 DNA 维持基因座(除其他外)作为修饰物,并暗示了发病机制的两步机制:致病 HTT CAG 重复的体细胞不稳定性,随后触发神经元损伤。最大的研究仅限于具有评分者估计运动起始年龄的 HD 个体。为了充分利用几个大型 HD 自然史研究中的丰富表型数据,我们通过使用常见的运动和认知测量来进行算法预测,以预测其他疾病标志物的年龄,作为 GWAS 的附加表型。与 Trans-Omics for Precision Medicine 参考面板的内插相结合,使用综合测量进行的预测提供了具有更大检测能力的客观地标表型,以检测大多数修饰基因座。重要的是,通过比较 MSH3 和 FAN1 上的常见修饰物,各个基因座之间的相对修饰信号存在显著差异,这表明个体修饰物效应可以优先在运动或认知领域起作用。因此,DNA 维持修饰机制的单个组件可能会对相应临床测量所基于的神经元回路产生不同的作用。此外,我们还在 PMS1 和 PMS2 基因座中鉴定到了其他修饰物效应,并暗示了 7 号染色体上的潜在第二个基因座。这些发现表明,基于其他定量或定性表型,扩大对 HD 遗传修饰物的发现和特征描述不仅有望提供经过人体验证的治疗靶点,而且还提供了一种方法来剖析亨廷顿病发病机制中体细胞不稳定性和毒性成分所涉及的机制和细胞类型。